In another phase I trial for prostate cancer, a vaccine containing two irradiated prostate cancer cell lines that express GM-CSF (GVAX-PCa) again in combination with targeting the immune suppressive immune checkpoint molecule CTLA-4 by ipilimumab, induced an increased expression of CD40 by DCs. The gene discussed is CSF2; the disease is prostate carcinoma.